ライフサイエンスコーパス: central line

1 mmendation that it be administered through a central line.

2 continued hospitalization or placement of a central line.

3 bloodstream infections were associated with central lines, 86% of nosocomial pneumonia was associate

4 Bacteremia from frequent central line access was the most common problem.

5 were ventilated, received antibiotics, had a central line, and had 1 additional risk factor (parenter

6 Central line associated bloodstream infections (CLABSIs)

7 Central line-associated bloodstream infection (BSI) rate

8 We describe central line-associated bloodstream infection (CLABSI) p

9 entionists (IPs) conducting surveillance for central line-associated bloodstream infection (CLABSI) w

10 gest period a central line remains free from central line-associated bloodstream infection during an

11 nfection control precautions on our rates of central line-associated bloodstream infection in critica

12 Incidence of central line-associated bloodstream infection in the med

13 pin significantly decreased the incidence of central line-associated bloodstream infection in the med

14 The incidence of central line-associated bloodstream infection per 1000 p

15 days to the end of day 9, giving an adjusted central line-associated bloodstream infection rate of 0.

16 ished by the end of day 7 giving an adjusted central line-associated bloodstream infection rate of 1.

17 An adjusted central line-associated bloodstream infection rate was c

18 central line removed by day 7, zero risk for central line-associated bloodstream infection should be

19 The lowest probability identified for central line-associated bloodstream infection was 1 in 1

20 ection-free before the lowest probability of central line-associated bloodstream infection, 1 in 100

21 density of ventilator-associated pneumonia, central line-associated bloodstream infection, and cathe

22 nocycline and rifampin use and a decrease in central line-associated bloodstream infection, because o

23 tion, Clostridium difficile infection (CDI), central line-associated bloodstream infection, ventilato

24 ontrol group for 14 outcomes (ICU mortality, central line-associated bloodstream infection, ventilato

25 e unit were subjects for the surveillance of central line-associated bloodstream infection.

26 rifampin are proven to decrease the rates of central line-associated bloodstream infection; however,

27 95% CI, -31% to -1%; P = .03) and 64% fewer central line-associated bloodstream infections (3.4 vs 9

28 mary prespecified outcome was a composite of central line-associated bloodstream infections (CLABSIs)

29 acy of antimicrobial lock therapy to prevent central line-associated bloodstream infections (CLABSIs)

30 Factors that increase the risk of central line-associated bloodstream infections (CLABSIs)

31 ify 2 cohorts: (1) nondialysis patients with central line-associated bloodstream infections (CLABSIs)

32 quality improvement interventions to prevent central line-associated bloodstream infections (CLABSIs)

33 Healthcare-associated central line-associated bloodstream infections (CLABSIs)

34 nvolving evidence-based practices to prevent central line-associated bloodstream infections and the C

35 ion and providing further evidence that most central line-associated bloodstream infections are preve

36 pact of quality improvement interventions on central line-associated bloodstream infections in adult

37 positive bloodstream infections and possible central line-associated bloodstream infections in preter

38 Baseline average central line-associated bloodstream infections per 1,000

39 nterventions contribute to the prevention of central line-associated bloodstream infections.

40 he multifaceted intervention and the reduced central line-associated bloodstream infections.

41 The incidence of MRSA central line-associated BSI has been decreasing in recen

42 In all ICU types, MSSA central line-associated BSI incidence declined from 1997

43 From 2001 through 2007, MRSA central line-associated BSI incidence declined significa

44 = .02) in the 1997-2007 period, overall MRSA central line-associated BSI incidence decreased 49.6% (P

45 coronary units experienced increases in MRSA central line-associated BSI incidence in the 1997-2001 p

46 Declines in MRSA central line-associated BSI incidence ranged from -51.5%

47 07 were used to calculate pooled mean annual central line-associated BSI incidence rates for 7 types

48 sion modeling to estimate percent changes in central line-associated BSI metrics over the analysis pe

49 fection preventionist and computer algorithm central line-associated BSI rates were 3.3 (interquartil

50 Unit-specific central line-associated BSI rates were calculated for 12

51 stitutional comparisons of publicly reported central line-associated BSI rates.

52 ant variation in the application of standard central line-associated BSI surveillance definitions acr

53 Variation in central line-associated BSI surveillance practice may co

54 patient-days of surveillance; 2498 reported central line-associated BSIs (7.4%) were MRSA and 1590 (

55 Although the overall proportion of S. aureus central line-associated BSIs due to MRSA increased 25.8%

56 SA was defined as the proportion of S aureus central line-associated BSIs that were MRSA.

57 Overall, 33,587 central line-associated BSIs were reported from 1684 ICU

58 coccal biofilms are the most common cause of central-line-associated bloodstream infections, and anti

59 ject will not be limited to an infinitesimal central line but will have a finite extent, which is rel

60 s in diagnostic criteria and improvements in central line care.

61 We tested a novel, central line catheter-based, transvenous phrenic nerve p

62 The Lokich regimen was associated with more central line complications and hand-foot syndrome.

63 the presence of a right-sided aortic arch, a central line could be erroneously inserted into the arte

64 oup also reduced infection rates to <1/1,000 central line days (a 69% reduction) at 12 months.

65 intervention group sustained rates <1/1,000 central line days at 19 months (an 81% reduction).

66 -associated bloodstream infections per 1,000 central line days was 4.48 and 2.71, for the interventio

67 medical-surgical ICUs (0.31 vs 0.15 per 1000 central line days) to -69.2% (95% CI, -57.9% to -77.7%;

68 001) in surgical ICUs (0.24 vs 0.10 per 1000 central line days) to -77.7% (95% CI, -68.2% to -84.4%;

69 001) in surgical ICUs (0.58 vs 0.18 per 1000 central line days).

70 .001) in medical ICUs (0.40 vs 0.09 per 1000 central line days).

71 a total of 10,866 CLABSI cases and 9,543,765 central line days.

72 bloodstream infections (3.4 vs 9.4 per 1000 central line days; ratio, 0.36; 95% CI, 0.16 to 0.81; P

73 e rates, and CLABSI incidence rates per 1000 central line-days were calculated.

74 tional surveillance (2.4 infections per 1000 central line-days) had the highest rate by computer algo

75 computer algorithm (12.6 infections per 1000 central line-days).

76 and 9.0 (IQR, 6.3-11.3) infections per 1000 central line-days, respectively.

77 epresenting 241,518 patient-days and 165,963 central line-days.

78 Compliance with the insertion bundle for central lines during the first 12-month roll-out period

79 ith prior antibiotic exposure, presence of a central line, endotracheal intubation, and prior fungal

80 dulafungin administration into the heart via central line, exposure is likely extreme enough to induc

81 onal isolates of bacteremia in patients with central lines in an oncology ward (OW), with comparison

82 factors were effort-related (87%) in G1 and central lines in G2neonates (100%) and in G2non-neonates

83 eceive arsenic trioxide because of transient central line-induced cardiac arrhythmia, and another rec

84 ed 2 infectious complications (pneumonia and central line infection, both requiring hospitalization)

85 d an episode of severe sepsis secondary to a central line infection, treatment of sepsis is discussed

86 rovement interventions to reliably implement central line insertion and maintenance bundles on CLABSI

87 All patients in whom subclavian central line insertion is planned should have both sides

88 , lower extremity fracture, pelvic fracture, central line, intracranial hemorrhage, and blood transfu

89 es the presence of a predominant clone among central line isolates from an OW that is not present in

90 In case of any difficulties with central lines, it is necessary to investigate the underl

91 here were small changes in the extent of the central line of block.

92 only demonstrate that the PP-InsPs provide a central line of communication between signaling and meta

93 tion from a discrete midlateral right atrial central line of conduction block to the inferior vena ca

94 Because the central line of Gd(2)@C(79)N is due to the Kramer's doub

95 Despite a central line of research aimed at quantifying relationsh

96 Thus, in patients with permanent central lines or pacemakers, both corrected and uncorrec

97 Biofilm formation on central lines or peripheral catheters is a serious threa

98 e use: coagulase-negative staphylococci with central lines, P. aeruginosa and Acinetobacter species w

99 le donors had higher rates of AEs, requiring central line placement more often (17% vs 4%, P< .001),

100 y required critical care, blood transfusion, central line placement, mechanical ventilation, and surg

101 ose control and ultrasonography for reducing central-line placement complications.

102 Identify the longest period a central line remains free from central line-associated b

103 s of intensive care unit patients have their central line removed by day 7, zero risk for central lin

104 a catheter is low and, when obtained from a central line, statistically less than from a peripheral

105 The central line team at hospital cooperating with other spe

106 es regardless of the phase of the project or central line type.

107 For dialysis and unspecified central line types, the close to infection-free period w

108 inserted central catheters, and unspecified central line types.

109 resence of fever, comorbidities (intravenous central lines, urinary catheters, diabetes mellitus, AID

110 -lymphocyte preparations be administered via central line, vascular shunt, or arteriovenous fistula t

111 Intensive care unit adult patients whose central line was inserted in the intensive care unit.

112 lon, number of line infections, or number of central lines were found.

113 Central lines, which are essential for treating cancer,

114 The spectrum exhibits a central line with a sub-recoil linewidth as low as appro